Cocrystal Pharma price target lowered to $35 from $42 at H.C. Wainwright
The Fly

Cocrystal Pharma price target lowered to $35 from $42 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cocrystal Pharma to $35 from $42 and keeps a Buy rating on the shares. Last month, Cocrystal reported "highly favorable" safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study, the analyst tells investors in a research note. The firm sees a "substantial market opportunity" in the influenza space for the company.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on COCP:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App